- CA$46.29m
- CA$45.76m
- CA$0.07m
Brief: Diagnos To Submit Future CARA Version To FDA Before End Of Q3
Brief: Diagnos Welcomes Dr. Pierre-Luc Charlebois To Its Advisory Board
Brief: Validated For Global Scale Diagnos Passes Annual MDSAP Audit, Solidifying The Pathway To Approvals With Health Canada & FDA
Brief: Diagnos Provides Update On Its Health Canada Medical Device Licence Application
Brief: Diagnos Announces Closing Of Private Placement
Brief: Diagnos Inc - Tristram Coffin Ceased To Be An Insider Of Corporation Since His Ownership Dropped Below 10%
Brief: Diagnos Announces Closing Of Private Placement And Exercise Of Stock Warrants
Brief: Diagnos Continues Expansion In Canada With Kick-Off Of Services In Endocrinology Clinics With Distribution Partner Labtician Ophthalmics
Brief: Diagnos Reports Extension Of Its Contract With Novo Nordisk
Brief: Diagnos Announces Closing Of Private Placement And New Marketing Director
Brief: Diagnos Provides Corporate Update For 2021 And Outlook For 2022
Brief: DIAGNOS Reports Multi-Year Contract with Juarez Health & Medical Tourism Cluster
Brief: Diagnos Reports 3-Year Contract With Cielo Vista Eye Clinic In Mexico
Brief: Diagnos Renews Contract With Optina Diagnostics For Alzheimer's Disease Early Detection
Brief: Diagnos Initiates A Clinical Trial Study In The Usa For Early Detection And Prevention Of Stroke Using Its New Application Cara-Stroke
Brief: DIAGNOS Announces Further Deployment Of Its AI Based CARA Technology In Saudi Arabia
Brief: Diagnos Inc- Management Is Unaware Of Any Material Change In Corp's Operations That Would Account For Recent Increase In Market Activity
Brief: Diagnos Inc to resume Screening Operations In Saudi Arabia
Brief: Diagnos Announces A Multi-Year Contract With Chaparral Medical Group In California